https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(MedPage Today) — Topline data showed that an investigational gene therapy slowed Huntington’s disease progression and met its primary endpoint in a pivotal trial, uniQure Biopharma announced Wednesday.
A high-dose version of the treatment, known…
